Breckenridge Duloxetine Future Refund Program Settlement — Claim Deadline January 1, 2028

Breckenridge Duloxetine future refund program settlement
Photo by Towfiqu barbhuiya on Pexels

Breckenridge Duloxetine Future Refund Program Settlement

Breckenridge Pharmaceutical has established a Future Refund Program as part of a nationwide class action settlement over duloxetine (generic Cymbalta) contaminated with nitrosamine impurities — carcinogenic compounds. Multiple recalls between 2024 and 2025 covered approximately 70 million pills. If you purchased recalled Breckenridge duloxetine, you may be eligible for a refund. File your claim by January 1, 2028.

What Is This Case About?

The lawsuit, Boyer v. Breckenridge Pharmaceutical, Inc., alleges that Breckenridge manufactured and sold duloxetine (the generic version of Cymbalta, an antidepressant) contaminated with nitrosamine impurities — compounds classified as probable carcinogens. Multiple recalls occurred between 2024 and 2025, covering approximately 70 million pills. The settlement received final court approval following a Fairness Hearing on September 23, 2025.

Who Is Eligible?

Everyone in the United States who purchased Breckenridge-manufactured duloxetine. Those who purchased recalled batches may qualify for higher payments. The Future Refund Program specifically covers out-of-pocket costs for unused, returned duloxetine subject to product recalls occurring after May 22, 2025.

What Benefits Are Available?

  • Cash compensation for purchases of the contaminated drug
  • Higher payments for those who purchased specifically recalled lots
  • Future Refund Program: Monetary reimbursement for out-of-pocket costs on unused, returned recalled product

How to File Before the Deadline

Submit your claim through the official Breckenridge Future Refund Program website or the Boyer Settlement website. For the Future Refund Program, after submitting your claim, you will receive a Return Authorization and shipping label to mail back unused pills.

Looking for more open class action settlements? Visit OpenClassActions.com to browse current cases you may qualify for.

  • Claim Deadline: January 1, 2028
  • Case Type: Pharmaceutical — contaminated generic medication

OpenClassActions.org is not affiliated with Breckenridge Pharmaceutical or the settlement administrator. This page is for informational purposes only and does not constitute legal advice.